Skip to main content
Premium Trial:

Request an Annual Quote

NanoString NCounter Vantage 3D Panels

NanoString Technologies has launched two new translational research assays, nCounter Vantage 3D DNA (SNV) Solid Tumor panel and nCounter Vantage 3D Protein Solid Tumor Signaling Pathways panel. The nCounter Vantage 3D DNA (SNV) Solid Tumor panel is designed for highly multiplexed profiling of known cancer mutations, as well as insertion and deletions from as little as five nanograms of DNA, while the nCounter Vantage 3D Solid Tumor Signaling Pathways panel enables the identification of activation state through the measurement of total proteins and phosphoproteins from a single slice of FFPE tissue or form as little as 250 ng of protein from cell or tissue lysate. The two new panels can be combined with one another as well as with the nCounter Vantage RNA panels to enable more comprehensive profiling of formalin-fixed, paraffin embedded tumor tissue.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.